New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 8, 2014
05:49 EDTBSXBoston Scientific presents data on Precision Spectra SCS
New retrospective data highlighting the Boston Scientific Precision Spectra Spinal Cord Stimulator, or SCS, System demonstrate the device provided sustained and highly significant relief of low-back pain six months after implantation. The retrospective study of 213 patients at 13 centers is focused on patients with chronic pain who were treated with the Precision Spectra SCS System. To date, 140 patients have reached six months post-implant. Results include: Sustained and highly significant reduction in pain from an average baseline score of 7.15, on a 10-point scale, to an average score of 2.93 at six months post-implant. In those patients with only low-back pain, sustained and highly significant reduction of low back pain, from an average baseline score of 7.53, on a 10-point scale, to an average of 3.45 at six months post-implant. In those patients with severe low back pain, sustained and highly significant reduction in pain, from an average score of 8.78 at baseline to 3.68 at 6 months post-implant.
News For BSX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 20, 2015
16:09 EDTBSXBoston Scientific announces long-term data underscore safety, efficacy of S-ICD
The Journal of the American College of Cardiology published data confirming the long-term safety and efficacy of the Boston Scientific S-ICD System for patients at risk of sudden cardiac arrest. The study, "Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-year Results from a Pooled Analysis of the IDE Study and EFFORTLESS Registry" was led by Dr. Martin Burke, professor of medicine at the University of Chicago. The analysis combined data from two large S-ICD studies to provide the most comprehensive look at S-ICD System patient outcomes to date. The all-cause mortality rate for the S-ICD patients was 1.6% per year, comparing favorably to observed mortality rates in similar TV-ICD studies. Currently, the S-ICD System is covered nationally by Medicare, Aetna, Cigna and others, and regionally by numerous private and Medicaid plans, providing coverage for approximately 170M individuals in the U.S. The S-ICD System has been commercially available in Europe since 2009.
07:44 EDTBSXSurvey shows strong momentum for Boston Scientific devices, says RBC Capital
RBC Capital says that its survey supports strong momentum for Boston Scientific's S-ICD and Watchman, and the firm thinks the company is probably gaining share in single-chamber ICDs. The firm raised its price target on the shares to $20 from $17 and recommends buying the shares at current levels or on pullbacks.
April 16, 2015
16:11 EDTBSXBoston Scientific enrolls first patient REDUCE-HTN: REINFORCE study
Boston Scientific announced the first patient in the REDUCE-HTN: REINFORCE study was enrolled this week at Cardiology P.C. at Princeton Baptist Medical Center in Birmingham, AL by Farrell Mendelsohn, M.D., site principal investigator, and referred by Michael Wilensky, M.D. Boston Scientific received an investigational device exemption, or IDE, for the study from the FDA in December.
April 14, 2015
09:09 EDTBSXBoston Scientific announces strategic alliance with Frankenman
Boston Scientific announced the signing of a strategic alliance with Frankenman Medical Equipment Company, a recognized leader with deep local market expertise in the China surgical devices market. This alliance is expected to enable Boston Scientific and Frankenman to reach more clinicians and treat more patients by providing access to training on less invasive endoscopic technologies and the clinical and economic benefits these therapies can provide. CPEChina Fund, an entity of CITIC PE, is a current shareholder of Frankenman and will continue to support the company's growth in alignment with this strategic partnership.Under the terms of the agreement, Boston Scientific will become a shareholder of Frankenman, and provide services and expertise to Frankenman to support its continued growth, development pipeline and manufacturing capabilities. The transaction is expected to close in the first half of 2015, subject to customary closing conditions.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use